Connect with us
Information

WORLD EDITION
Australia
North America
World

Investing News NetworkYour trusted source for investing success

WORLD EDITION
North America
Australia
World
My INN

Private Placements

Reports & Guides
- Market Outlook Reports
- Investing Guides

Precious Metals
Battery Metals
Base Metals
Energy
Critical Metals

nasdaq:regn:us

POPULAR ARTICLES

Dupixent® Recommended for EU Approval by the CHMP to Treat Patients with COPD

Dupixent® Recommended for EU Approval by the CHMP to Treat Patients with COPD

Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation

Update on FDA Priority Review of Dupixent® for the Treatment of COPD Patients with Type 2 Inflammation

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors

Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors

LATEST ARTICLES

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 in Combination with Libtayo® to be Reported at ASCO

Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 in Combination with Libtayo® to be Reported at ASCO

Dupixent® Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

Dupixent® Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in The New England Journal of Medicine

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc.

Kirby McInerney LLP is Investigating Potential Shareholder Claims Against Regeneron Pharmaceuticals, Inc.

Dupixent® sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

Dupixent® sBLA Accepted for FDA Priority Review for Treatment of Adolescents with Chronic Rhinosinusitis with Nasal Polyposis

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

Regeneron Announces Investor Conference Presentations

Regeneron Announces Investor Conference Presentations

Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals Inc.

Latest News

Pinnacle Arranges Non-Brokered Private Placement

Stallion Uranium Announces the Completion of Coyote Project 3D Gravity Inversion

Apollo Silver Enters into Investor Relations Agreement

Sun Summit Commences Drilling and Provides Exploration Update from the JD Project in BC's Toodoggone District

Silver Crown Royalties Closes Final Tranche of its Non-Brokered Private Placement

Outlook Reports

Precious Metals
- Gold
- Silver
Battery Metals
Energy
- Uranium
- Oil and Gas

Base Metals
Critical Metals
- Rare Earths
Industrial Metals
Agriculture

- Cleantech
- Emerging Tech

- Biotech
- Cannabis

- Psychedelics
- Pharmaceuticals

Featured Stocks

Avanti Gold

AGC:CC

Maritime Resources

MAE:CC

Triumph Gold

TIG:CA

Quimbaya Gold

QIM:CC

New Age Exploration

NAE:AU

Asara Resources

AS1:AU

More featured stocks

Browse Companies

Precious Metals
Battery Metals
Energy

Base Metals
Critical Metals

MARKETS

COMMODITIES

CURRENCIES